DNA methylation analysis supported this relationship, indicating that the categorization of sarcomas with TFCP2 fusions as RMS should be revisited and underscoring the potential of multilayered molecular profiling to refine and sometimes revise conventionally defined disease categories. Here, TFCP2 is linked to sarcoma.